A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopietic Stem Cell Transplant
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2018
At a glance
- Drugs Defibrotide (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals plc
- 17 Jun 2018 Trial design presented at the 23rd Congress of the European Haematology Association
- 23 Feb 2018 According to a Jazz Pharmaceuticals media release, first patient has been enrolled.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting, according to a Jazz Pharmaceuticals media release.